



(11) **EP 2 196 538 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
01.10.2014 Bulletin 2014/40

(51) Int Cl.:
A61K 47/48 ^(2006.01) **A61K 38/00** ^(2006.01)
C12N 9/06 ^(2006.01) **C12N 9/96** ^(2006.01)

(21) Application number: **10158016.5**

(22) Date of filing: **07.02.2001**

(54) **Conjugates prepared with aggregate-free proteins**

Konjugate, die mit Aggregat-freien Proteinen hergestellt wurden

Conjugués préparés avec des protéines sans agrégats

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **10.02.2000 US 501730**

(43) Date of publication of application:
16.06.2010 Bulletin 2010/24

(60) Divisional application:
10180428.4 / 2 305 819

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
01923265.1 / 1 254 237

(73) Proprietors:
• **Mountain View Pharmaceuticals, Inc.**
Menlo Park, CA 94025-1813 (US)
• **Duke University**
Durham, NC 27705 (US)

(72) Inventors:
• **Sherman, Merry R.**
San Carlos, CA 94070 (US)
• **Saifer, Mark G. P.**
San Carlos, CA 94070 (US)
• **Williams, L. David**
Fremont, CA 94536 (US)
• **Hershfield, Michael S.**
Durham, NC 27707 (US)
• **Kelly, Susan J.**
Chapel Hill, NC 27516 (US)

(74) Representative: **Evenson, Jane Harriet et al**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A-00/07629 WO-A1-87/00056
WO-A1-92/16221 WO-A1-94/23740

- **YASUDA Y ET AL: "Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 38, no. 7, July 1990 (1990-07), pages 2053-2056, XP002125209 ISSN: 0009-2363**
- **DAVIS S ET AL: "HYPOURICAEMIC EFFECT OF POLYETHYLENEGLYCOL MODIFIED URATE OXIDASE" LANCET THE, LANCET LIMITED. LONDON, GB, 8 August 1981 (1981-08-08), pages 281-283, XP000577404 ISSN: 0140-6736**
- **SAVOCA K V ET AL: "Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase" INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, BASEL, CH, vol. 75, 1984, pages 58-67, XP002125212 ISSN: 0020-5915**
- **BURNHAM N L: "POLYMERS FOR DELIVERING PEPTIDES AND PROTEINS" AMERICAN JOURNAL OF HOSPITAL PHARMACY, AMERICAN SOCIETY OF HOSPITAL PHARMACISTS, BETHESDA, MD, US, vol. 51, no. 2, 15 January 1994 (1994-01-15), pages 210-218, XP000783643 ISSN: 0002-9289**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 196 538 B1

- SHARMA ET AL: "Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes", BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 25, no. 3, 31 March 2007 (2007-03-31) , pages 325-331, XP022014886, ISSN: 0734-9750, DOI: DOI: 10.1016/J.BIOTECHADV.2007.01.007
- ROSENBERG A S: "Effects of protein aggregates: An Immunologic Perspective", AAPS JOURNAL, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, US, vol. 8, no. 3, 4 August 2006 (2006-08-04), pages E501-E507, XP003021154, ISSN: 1550-7416, DOI: DOI: 10.1208/AAPSJ080359

DescriptionStatement of Government Rights in the Invention

5 **[0001]** A portion of the research described in this application was made with support from the U.S. Israel Binational Industrial Research and Development Foundation. Accordingly, the U.S. Government may have certain rights in the invention.

Background of the Invention

10 **[0002]** The present invention relates to purification and chemical modification of proteins to prolong their circulating lifetimes and reduce their immunogenicity. More specifically, the invention relates to the removal of aggregates larger than octamers from urate oxidases (uricases) prior to conjugation of poly(ethylene glycols) or poly(ethylene oxides). This substantially eliminates uricase immunogenicity without compromising its uricolytic activity.

Description of the Related Art

20 **[0003]** Statements contained in this background section do not constitute an admission of prior art, but instead reflect the inventors' own subjective comments on and interpretations of the state of the art at the time the invention was made. These interpretations may include personal, heretofore undisclosed, insights of the inventors, which insights were not themselves part of the prior art.

25 **[0004]** Urate oxidases (uricases; E.C. 1.7.3.3) are enzymes that catalyze the oxidation of uric acid to a more soluble product, allantoin, a purine metabolite that is more readily excreted. Humans do not produce enzymatically active uricase, as a result of several mutations in the gene for uricase acquired during the evolution of higher primates. Wu, X, et al., (1992) J mol Evol 34:78.84. As a consequence, in susceptible individuals, excessive concentrations of uric acid in the blood (hyperuricemia) and in the urine (hyperuricosuria) can lead to painful arthritis (gout), disfiguring urate deposits (tophi) and renal failure. In some affected individuals, available drugs such as allopurinol (an inhibitor of uric acid synthesis) 30 produce treatment-limiting adverse effects or do not relieve these conditions adequately. Hande, KR, et al., (1984) Am J Med 76:47-56; Fam, AG, (1990) Baillière's Clin Rheumatol 4:177- 192. Injections of uricase can decrease hyperuricemia and hyperuricosuria, at least transiently. Since uricase is a foreign protein in humans, however, even the first injection of the unmodified protein from *Aspergillus flavus* has induced anaphylactic reactions in several percent of treated patients (Pui, C-H, et al., (1997) Leukemia 11:1813-1816), and immunologic responses limit its utility for chronic or intermittent 35 treatment. Donadio, D, et al., (1981) Nouv Presse Méd 10:711-712; Leautic, M, et al., (1983) Rev Rhum Mal Osteoartic 50:553-554.

[0005] U.S. Patent Application Serial No. 09/370,084 and published International Application No. PCT/US99/17514, disclose poly (ethylene glycol)-urate oxidase (PEG-uricase) that retains at least about 75% of the uricolytic activity of unconjugated uricase and has substantially reduced immunogenicity. In one such purified uricase, each subunit is covalently linked to an average of 2 to 10 strands of PEG, wherein each molecule of PEG may have a molecular weight 40 between about 5 kDa and 100 kDa.

[0006] The aggregation of proteins is known to increase their immunogenicity. This understanding has contributed to the development of methods for intentionally aggregating proteins by treatments such as thermal denaturation and cross-linking by exposure to glutaraldehyde prior to use in the preparation of vaccines or for immunization of animals to produce 45 antisera.

[0007] Unintentional aggregation of proteins has also been recognized as contributing to immunization or sensitization during clinical use of therapeutic proteins, e.g. for human gamma globulin (Henney et al. (1968) N. Engl. J. Med. 278:2244-2246) and for human growth hormone (Moore et al. (1980) J. Clin. Endocrinol Metab. 51:691-697). The contribution of aggregates to the immunogenicity of human interferon alpha has been demonstrated in BALB/c mice (Braun et al. (1997) Pharm. Res. 14:1472-1478) and an enzyme-linked immunosorbent assay (ELISA) has been developed for their measurement (Braun et al. (1997) Pharm. Res. 14:1394-1400). 50

[0008] In contrast to the known effects of aggregation on the immunogenicity of proteins, there are not reports of the effect of aggregation on the immunogenicity of proteins conjugated to poly(alkylene glycols) such as PEG. There is a need for poly(alkylene glycol)-uricase conjugates that substantially eliminate uricase immunogenicity without compromising its uricolytic activity. The present invention provides such compositions. 55

[0009] WO 00/07629 describes peg-urate oxidase conjugates.

[0010] WO 87/00056 describes solubilisation of proteins for pharmaceutical compositions using polymer conjugation.

[0011] WO 92/16221 describes pegylation of polypeptides.

[0012] WO 94/23740 describes conjugates of growth factor and a bone resorption inhibitor.

[0013] Sharma et al., *Biotechnology Advances* (2007) vol 25(3):325-331, describe immunogenicity of therapeutic proteins.

[0014] Rosenberg et al. *AAPS Journal* (2006) vol8(3):E501-E507 describe effects of protein aggregates from an immunological perspective.

Summary of the Invention

[0015] The present invention is defined by the claims.

Summary of the Disclosure

[0016] Conjugation of proteins with poly(alkylene glycols), especially PEG, produces conjugates with reduced immunogenicity and increased persistence in the bloodstream. In attempting to produce substantially non-immunogenic conjugates of uricase that retain substantially all of the uricolytic activity of the unmodified uricase preparation, it was discovered that traces of large aggregates of uricase in the starting material were surprisingly effective at provoking both antibody formation and accelerated clearance from the circulation, both of which are deleterious, after repeated injections of PEG conjugates prepared from uricase containing such aggregates. Surprisingly, the present inventors found that the increased immunogenicity and accelerated clearance were *not* due to the presence of well-defined, moderate-sized aggregates of the uricase subunit that are larger than the native tetramer, e.g. aggregates containing eight subunits (octamers). The octameric form of uricase is present at sufficiently high concentrations in most preparations of uricase to be detectable by its absorbance of UV light, e.g. at 214 nm or 276 nm, or by its contribution to the refractive index or other measurements of protein concentration. Nevertheless, the octamers themselves were found to contribute minimally to the immunogenicity and accelerated clearance of PEG-uricase conjugates, in contrast with the much smaller quantities of the much larger aggregates that are undetectable by UV absorbance under the conditions tested but are readily detected by static (Rayleigh) or dynamic light scattering. Therefore, the removal of such traces of very large aggregates prior to conjugation with PEG was found to decrease the immunogenicity and the accelerated clearance of the resultant PEG-uricase conjugates to a surprising extent.

[0017] The specification describes purified urate oxidase (uricase) substantially free of aggregates larger than octamers. Preferably, the uricase is mammalian uricase. More preferably, the uricase is porcine liver, bovine liver or ovine liver uricase. In one aspect of this disclosure the uricase is recombinant. In another aspect of this disclosure, the uricase has substantially the sequence of porcine, bovine, ovine or baboon liver uricase. Advantageously, the uricase is chimeric. Preferably, the uricase is PKS uricase. In another aspect of this disclosure, the uricase has substantially the sequence of baboon liver uricase in which tyrosine 97 has been replaced by histidine. Preferably, the uricase comprises an amino terminus and a carboxy terminus, and wherein the uricase is truncated at one terminus or both termini. Advantageously, the uricase is a fungal or microbial uricase. Preferably, the fungal or microbial uricase is isolated from *Aspergillus flavus*, *Arthrobacter globiformis*, *Bacillus sp.* or *Candida utilis*, or is a recombinant enzyme having substantially the sequence of one of said uricasases. Alternatively, the uricase is an invertebrate uricase. Preferably, the invertebrate uricase is isolated from *Drosophila melanogaster* or *Drosophila pseudoobscura*, or is a recombinant enzyme having substantially the sequence of one of said uricasases. In another aspect of this disclosure, the uricase is a plant uricase. Preferably, the plant uricase is isolated from root nodules of *Glycine max* or is a recombinant enzyme having substantially the sequence of the uricase.

[0018] In one aspect of this disclosure, the uricase described above is conjugated to poly(ethylene glycol) or poly(ethylene oxide), under conditions such that the uricase in the conjugate is substantially free of aggregates larger than octamers. Preferably, the uricase is conjugated to poly(ethylene glycol) or poly(ethylene oxide) via a urethane (carbamate), secondary amine or amide linkage. In one aspect of this disclosure, the poly(ethylene glycol) is monomethoxy poly(ethylene glycol). In another aspect of this disclosure, the poly(ethylene glycol) or poly(ethylene oxide) has a molecular weight between about 5 kDa and 30 kDa. Preferably, the poly(ethylene glycol) or poly(ethylene oxide) has a molecular weight between about 10 kDa and 20 kDa. Advantageously, the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) is between about 2 and 12 strands per uricase subunit. More advantageously, the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) is between about 6 and 10 per uricase subunit. Most advantageously, the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) is between about 7 and 9 per uricase subunit. Preferably, the poly(ethylene glycol) or poly(ethylene oxide) is linear. Alternatively, the poly(ethylene glycol) or poly(ethylene oxide) is branched.

[0019] The present specification describes a pharmaceutical composition for lowering uric acid levels in a body fluid or tissue, comprising the uricase conjugate described above and a pharmaceutically acceptable carrier. Preferably, the composition is stabilized by lyophilization and dissolves upon reconstitution to provide solutions suitable for parenteral administration.

[0020] Another disclosure of the specification is a method for purifying uricase having reduced immunogenicity, comprising the step of separating uricase aggregates larger than octamers in uricase fractions, and excluding such aggregates from the purified uricase. Preferably, the separating step comprises the step of detecting aggregates larger than octamers from at least a portion of the uricase fractions and excluding the fractions containing the aggregates. Advantageously, the detecting step comprises measurement of light scattering.

[0021] The present specification describes isolated uricase prepared by the method described above.

Brief Description of the Drawings

[0022]

Figure 1 illustrates uricase activity, total protein and salt concentrations in fractions from a Pharmacia Biotech Mono Q (1 x 10 cm) anion exchange column. Uricase activity was measured at room temperature by monitoring the decrease in absorbance at 292 nm of 100 μ M uric acid in 200 mM sodium borate, pH 9.2. Total protein was determined from the area under the curve of the absorbance peak of uricase in size-exclusion HPLC analyses.

Figure 2 illustrates size-exclusion HPLC analysis on a Pharmacia Superdex 200 column (1 x 30 cm) of the load and selected fractions from a preparative Mono Q chromatography of porcine uricase containing the mutations R291K and T301S (PKS uricase) showing data obtained by a light-scattering detector at 90°C (upper curves) and by absorbance at 276 nm (lower curves). The different signal strengths of the tetrameric, octameric and more highly aggregated forms of uricase in the unfractionated sample (load) and the various fractions are evident. The load was diluted 1/5 with Mono Q column buffer, fraction 5 was diluted 1/3 and fraction 6 was diluted 1/9. Fractions 5 and 6 were combined to form the "low salt pool"

Figure 3 illustrates size-exclusion analyses of fractions from the Mono Q column in Figure 1, showing data obtained by a light-scattering detector at 90° and by absorbance at 276 nm, as in Figure 2. The fractions shown in this figure were used to form the "high salt pool, from which PEG conjugates were prepared and injected into BALB/c mice. The resultant serum activities and immunologic responses in BALB/c mice are shown in Figures 5 and 6.

Figure 4 illustrates octamer content, determined by absorbance at 276 nm and by light scattering at 90°, calculated from the data in Figures 2 and 3, of unfractionated PKS uricase and of selected fractions from the preparative MonoQ column chromatography of PKS uricase (Figure 1).

Figure 5 illustrates UV assays, as in Figure 1, of uricase activity after a 4-hour incubation at 37°C, in sera drawn 24 hours after each of six weekly injections of 6 x 10-kDa PEG conjugates of PKS uricase or of pools from Mono Q column fractions.

Figure 6 illustrates ELISA analyses of IgG antibody formation against PEG conjugates of PKS uricase and against PEG conjugates of the pools of fractions from the Mono Q column shown in Figure 1, in sera drawn 24 hours after each of six weekly injections of female BALB/c mice with 0.2 mg of uricase protein per 20 grams of body weight. For each mouse, data from bleedings 24 hours after the first through sixth injections are shown from left to right.

The assay conditions are described in Example 6. Data for the eight mice in each group were arranged in order of increasing immune response, from left to right.

Detailed Description of the Disclosure and Preferred Embodiments

[0023] Previous studies have shown that when a significant reduction in the immunogenicity and/ or antigenicity of uricase is achieved by conjugation with PEG (PEGylation), it is invariably associated with a substantial loss of uricolytic activity. The present disclosure includes the observation that traces of aggregates of urate oxidases larger than octamers substantially contribute to immunogenicity and the induction of accelerated clearance of PEG-uricase conjugates. This discovery is most likely applicable to proteins other than uricases, including interferons and growth factors.

[0024] The safety, convenience and cost-effectiveness of biopharmaceuticals are all adversely impacted by decreases in their potencies and the resultant need to increase the administered dose. Thus, there is a need for a safe and effective alternative means for lowering elevated levels of uric acid in body fluids, including blood and urine. The present specification describes a method for producing uricase that excludes uricase aggregates larger than octamers for use in the synthesis of PEG-uricase. This PEG-uricase retains all or nearly all of the uricolytic activity of the unmodified enzyme. The present specification describes purified uricase substantially free of aggregates larger than octamers. The term "substantially free" indicates that the purified uricase comprises no more than about 2%, and preferably no more than about 1% of aggregates larger than octamers.

[0025] The present specification describes a method for purifying uricase such that aggregates larger than octamers are excluded from the purified preparation. Because these larger aggregates are highly immunogenic, their presence in the purified uricase preparation is undesirable. The method involves monitoring column fractions by light scattering rather than or in addition to ultraviolet absorbance at 280 nm, because the aggregates may be too dilute to be detected

by ultraviolet absorbance. The purified uricase is then conjugated to water- soluble polymers, preferably poly(ethylene glycols) or poly(ethylene oxides) as described in copending U.S. Application Serial No. 09/370,084.

5 [0026] The removal of aggregated uricase from a preparation consisting predominantly of tetrameric uricase can be accomplished by any of the methods known to those skilled in the art, including size-exclusion chromatography, ion-exchange chromatography, ultrafiltration through a microporous membrane and centrifugation, including ultracentrifugation. The separation method may include separation and analysis of fractions and the rejection or exclusion of those fractions containing excessive quantities of large aggregates. The resultant uricase preparation is better suited for the synthesis of substantially non-immunogenic conjugates of uricase than is the unfractionated uricase. For chronic administration, it is important that PEG conjugates of proteins, e.g. PEG-uricase, have low immunogenicity and do not
10 provoke progressively more rapid clearance from the bloodstream after repeated doses.

[0027] The present specification describes pharmaceutical compositions of the polymer-uricase conjugates. These conjugates are substantially non-immunogenic and retain at least 75%, preferably 85%, and more preferably 95% or more of the uricolytic activity of the unmodified enzyme. Uricases suitable for conjugation to water- soluble polymers include naturally occurring urate oxidases isolated from bacteria, fungi and the tissues of plants and animals, both
15 vertebrates and invertebrates, as well as recombinant forms of uricase, including mutated, hybrid, and/or truncated enzymatically active variants of uricase. Water-soluble polymers suitable for use in the present invention include linear and branched poly(ethylene glycols) or poly(ethylene oxides), all commonly known as PEGs. Examples of branched PEG are the subject of U.S. Patent 5,643,575. One preferred example of linear PEG is monomethoxyPEG, of the general structure $\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n\text{H}$, where n varies from about 100 to about 2,300.

20 [0028] One disclosure of the present specification is a conjugate of urate oxidase (uricase) that retains at least about 75% of the uricolytic activity of unconjugated uricase and has substantially reduced immunogenicity. The uricase of this aspect of the disclosure may be recombinant. Whether recombinant or not, the uricase may be of mammalian origin. In one aspect of this disclosure, the uricase may be porcine, bovine or ovine liver uricase. In another aspect of this disclosure the uricase may be chimeric. The chimeric uricase may contain portions of porcine liver and) or baboon liver uricase.
25 For example, the chimeric uricase may be porcine uricase containing the mutations R291K and T301S (PKS uricase), Alternatively, the uricase may be baboon liver uricase in which tyrosine 97 has been replaced by histidine, whereby the specific activity of the uricase may be increased by at least about 60%. The uricase of the disclosure whatever the origin, may also be in a form that is truncated, either at the amino terminal, or at the carboxyl terminal, or at both terminals. Likewise, the uricase may be fungal or microbial uricase. In one aspect of this disclosure, the fungal or microbial uricase
30 may be a naturally occurring or recombinant form of uricase from *Aspergillus flavus*, *Arthrobacter globiformis*, *Bacillus sp.* or *Candida utilis*. Alternatively, the uricase may be an invertebrate uricase, such as, for example, a naturally occurring or recombinant form of uricase from *Drosophila melanogaster* or *Drosophila pseudoobscura*. The uricase of the disclosure may also be a plant uricase, for example, a naturally occurring or recombinant form of uricase from soybean root nodule (*Glycine max*). The PEG may have an average molecular weight between about 5 kDa and 100 kDa; preferably the PEG may have an average molecular weight between about 8 kDa and 60 kDa; more preferably, the PEG may have an average molecular weight between about 10 kDa and about 40 kDa, such as, for example, 10 to 20 kDa. The average number of covalently coupled strands of PEG may be 2 to 12 strands per uricase subunit; preferably, the average number of covalently coupled strands may be 6 to 10 per subunit; more preferably, the average number of strands of PEG may be 7 to 9 per subunit. In one aspect of this disclosure, the uricase may be tetrameric. The strands of PEG may be
35 covalently linked to uricase via urethane (carbamate) linkages, secondary amine linkages, and/or amide linkages. When the uricase is a recombinant form of any of the uricases mentioned herein, the recombinant form may have substantially the sequence of the naturally occurring form.

[0029] One preferred mammalian uricase is recombinant pig- baboon chimeric uricase, composed of portions of the sequences of pig liver and baboon liver uricase, both of which were first determined by Wu, *et al.*, (1989). One example
45 of such a chimeric uricase contains the first 288 amino acids from the porcine sequence (SEQ ID NO: 1) and the last 16 amino acids from the baboon sequence (SEQ ID NO: 2). Hershfield, *et al.*, international Publication WO 00/08196, Urate Oxidase, published February 17,2000. Since the latter sequence differs from the porcine sequence at only two positions, having a lysine (K) in place of arginine at residue 291 and a serine (S) in place of threonine at residue 301, this mutant is referred to as pig-K.S or PKS uricase (SEQ ID NO: 3). PKS uricase has one more lysine residue and, hence, one more potential site of PEGylation than either the porcine or baboon sequence.
50

[0030] The cDNAs for various mammalian uricases, including PKS uricase, were subcloned and the optimal conditions were determined for expression in *E. coli*, using standard methods. See Erlich, HA, (Ed.) (1989) PCR Technology. Principles and Applications for DNA Amplification. New York: Stockton Press; Sambrook, J, et al., (1989) Molecular Cloning. A laboratory Manual, Second Edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. The recombinant uricases were extracted, purified and their stability and activity were assessed using a modification of standard assays. See Fridovich, I, (1965) J Biol Chem 240:2491.2494; Nishimura, *et al.*, (1979), and Examples 1 and 5.
55

[0031] In one disclosure of the specification, uricase may be conjugated via a biologically stable, nontoxic, covalent linkage to a relatively small number of strands of PEG. Such linkages may include urethane (carbamate) linkages,

secondary amine linkages, and amide linkages. Various activated PEGs suitable for such conjugation are available commercially from Shearwater Polymers, Huntsville, AL.

5 [0032] For example, urethane linkages to uricase may be formed by incubating uricase in the presence of the succinimidyl carbonate (SC) or *p*-nitrophenyl carbonate (NPC) derivative of PEG. SC-PEG may be synthesized using the procedure described in U.S. Patent 5,612,460. NPC-PEG may be synthesized by reacting PEG with *p*-nitrophenyl chloroformate according to methods described in Veronese, FM, et al., (1985) Appl Biochem Biotechnol 11:141-152, and in U.S. Patent 5,286,637. The methods described in the '637 patent are adapted to PEGs of higher molecular weight by adjusting the concentrations of the reactants to maintain similar stoichiometry. An alternative method of synthesis of NPC-PEG is described by Büttner, W, et al., East German Patent Specification DD 279 486 A1.

10 [0033] Amide linkages to uricase may be obtained using an *N*-hydroxysuccinimide ester of a carboxylic acid derivative of PEG (Shearwater Polymers). Secondary amine linkages may be formed using 2,2,2-trifluoroethanesulfonyl PEG (tresyl PEG; Shearwater Polymers) or by reductive alkylation using PEG aldehyde (Shearwater Polymers) and sodium cyanoborohydride.

15 [0034] In conjugates containing PEG with a molecular weight of 10 kDa, the maximum number of strands of PEG that were coupled per subunit, while retaining at least 75% of the uricolytic activity of the unmodified enzyme, was about 12 strands for mammalian uricases (e.g., PKS uricase, a mutein of porcine uricase; see assay conditions in Example 5). The latter extent of PEGylation corresponds to about 40% of the total amino groups. In one disclosure of the specification, the average number of strands of PEG coupled per uricase subunit is between about 2 and 12. In a disclosure, the average number of strands of PEG coupled per uricase subunit is between about 6 and 10.

20 [0035] In a disclosure, the average number of covalently linked strands of PEG per uricase subunit is between about 7 and 9. In another disclosure, the molecular weight of PEG used for the coupling reaction is between about 5 kDa and 30 kDa, preferably between about 10 kDa and 20 kDa.

25 [0036] There are several factors that may affect the choice of the optimal molecular weight and number of strands of PEG for coupling to a given form of uricase. In general, the reduction or elimination of immunogenicity without substantial loss of uricolytic activity may require the coupling of relatively more strands of PEG of lower molecular weight, compared to relatively fewer strands of PEG of higher molecular weight. Likewise, each different form of uricase may have a different optimum with respect to both the size and number of strands. The optimal number of strands of PEG and PEG molecular weight can be readily determined using the methods described herein.

30 [0037] When PEG conjugates of mammalian uricase were prepared from the purified tetrameric and octameric forms of the enzyme (containing four or eight subunits of approximately 35 kDa), they displayed profoundly reduced immunogenicity in mice, in contrast to the moderate immunogenicity of PEG conjugates of uricase preparations containing large aggregates (see Figure 6) and the very high immunogenicity of the unmodified enzyme.

35 [0038] Purified preparations of naturally occurring and recombinant uricases usually contain a mixture of very large aggregates of the enzyme, in addition to the tetrameric (140-kDa) and the octameric (280-kDa) forms. The percentage of each uricase preparation that is in either the tetrameric or octameric form generally varies from about 20 % to 95% (see Figures 2-4). Despite evidence that unPEGylated aggregates of several other proteins are highly immunogenic (see, e.g., Moore, WV, et al., (1980) J Clin Endocrinol Metab 51:691-697), previous studies of PEG-uricase do not describe any efforts to limit the content of aggregates, suggesting that the potential immunogenicity of the PEG-modified aggregates was not considered. On the basis of the observations of the present inventors, it appears likely that such aggregates were present in the enzyme preparations used for previous syntheses of PEG-uricase. Their presence may have rendered the task of preparing non-immunogenic conjugates more difficult. It also appears that the large losses of uricolytic activity observed in previous efforts to PEGylate uricase were related to the large number of strands of low molecular weight PEG that were coupled. On the other hand, the methods of uricase purification and PEGylation described herein permit the covalent attachment of as many as 12 strands of PEG per subunit while retaining more than 75% of the uricolytic activity, at least for certain uricases, e.g., PKS uricase (a mutein of porcine uricase) and the enzyme from thermophilic *Bacillus sp.*

45 [0039] In another disclosure, substantially all large aggregates of the enzyme may be removed by ion-exchange chromatography (Figures 1-3) or size-exclusion chromatography at a pH between about 9 and 10.5, preferably 10.2, prior to conjugation of the resulting substantially aggregate-free preparation of uricase to PEG. The molecular weight of the uricase in each fraction from the preparative column may be monitored by any size dependent analytical technique, including, for example, HPLC, conventional size-exclusion chromatography, centrifugation, light scattering, capillary electrophoresis or gel electrophoresis in a non-denaturing buffer. For aggregate-free uricase isolated using size-exclusion chromatography, fractions containing only the 140-kDa and 280-kDa forms of the enzyme may be pooled and used for conjugation to PEG. For tetrameric plus octameric uricase isolated using ion-exchange chromatography, fractions from the ion-exchange column may be analyzed with respect to size to determine which fractions contain substantial amounts of the tetrameric and octameric forms without the large aggregates detected by light scattering. In the purified product, the undesirable large aggregates may thus constitute as little as about 1 %, or less, of the total uricase.

55 [0040] The results presented herein indicate that, even when extensively PEGylated, forms of PKS uricase larger than

the octamer provoke accelerated clearance (Figure 5) and are somewhat immunogenic in mice (Figure 6). In contrast, conjugates prepared from uricase that is essentially free of large aggregates (detectable by light scattering) could be reinjected at least six times at one-week intervals with much less evidence of accelerated clearance rates (Figure 5) and without the detectable formation of antibodies, as measured by a sensitive enzyme-linked immunoassay (Figure 6). The use of highly purified tetrameric or octameric uricase further distinguishes the improved conjugates of the present disclosure from the PEG-uricase preparations described previously. In contrast, the presence of a significant content of large aggregates in the uricase preparations used by some previous investigators may have led them to couple large numbers of strands of PEG in efforts to suppress the immunogenicity. Consequently, the enzymatic activity of the resultant conjugates was decreased substantially.

[0041] The PEG-uricase conjugates of the present disclosure are useful for lowering the levels of uric acid in the body fluids and tissues of mammals, preferably humans, and can thus be used for treatment of elevated uric acid levels associated with conditions including gout, tophi, renal insufficiency, organ transplantation and malignant disease. PEG-uricase conjugates may be injected into a mammal having excessive uric acid levels by any of a number of routes, including intravenous, subcutaneous, intradermal, intramuscular and intraperitoneal routes. Alternatively, they may be aerosolized and inhaled. See Patton, JS, (1996) *Adv Drug Delivery Rev* 19:3.36 and U.S. Patent 5,458,135. The effective dose of PEG-uricase of the present disclosure will depend on the level of uric acid and the size of the individual. In one embodiment of this aspect of the disclosure, PEG-uricase is administered in a pharmaceutically acceptable excipient or diluent in an amount ranging from about 10 μ g to about 1 g. In a , disclosure, the amount administered is between about 100 μ g and 500 mg. More preferably, the conjugated uricase is administered in an amount between 1 mg and 100 mg, such as, for example, 5 mg, 20 mg or 50 mg. Masses given for dosage amounts of the embodiments refer to the amount of protein in the conjugate.

[0042] Pharmaceutical formulations containing PEG-uricase can be prepared by conventional techniques, e.g., as described in Gennaro, AR (Ed.) (1990) *Remington's Pharmaceutical Sciences*, 18th Edition, Easton, PA: Mack Publishing Co. Suitable excipients for the preparation of injectable solutions include, for example, phosphate buffered saline, lactated Ringer's solution, water, polyols and glycerol. Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or non-aqueous liquids, dispersions, suspensions, or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. These formulations may contain additional components, such as, for example, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, buffers, antioxidants and diluents.

[0043] PEG-uricase may also be provided as controlled-release compositions for implantation into an individual to continually control elevated uric acid levels in body fluids. For example, polylactic acid, polyglycolic acid, regenerated collagen, poly-L-lysine, sodium alginate, gellan gum, chitosan, agarose, multilamellar liposomes and many other conventional depot formulations comprise bioerodible or biodegradable materials that can be formulated with biologically active compositions. These materials, when implanted or injected, gradually break down and release the active material to the surrounding tissue. For example, one method of encapsulating PEG-uricase comprises the method disclosed in U.S. Patent 5,653,974. The use of bioerodible, biodegradable and other depot formulations is expressly contemplated in the present invention. The use of infusion pumps and matrix entrapment systems for delivery of PEG-uricase is also within the scope of the present specification. PEG-uricase may also advantageously be enclosed in micelles or liposomes. Liposome encapsulation technology is well known in the art. See, e.g., Lasic, D, *et al.*, (Eds.) (1995) *Stealth Liposomes*. Boca Raton, FL: CRC Press.

[0044] The PEG-uricase pharmaceutical compositions of the disclosure will decrease the need for hemodialysis in patients at high risk of urate-induced renal failure, e.g., organ transplant recipients (see Venkataseshan, VS, *et al.*, (1990) *Nephron* 56:317-321) and patients with some malignant diseases. In patients with large accumulations of crystalline urate (tophi), such pharmaceutical compositions will improve the quality of life more rapidly than currently available treatments.

[0045] The following examples, which are not to be construed as limiting the invention in any way, illustrate the various aspects disclosed above. These examples describe PEG-uricases prepared by coupling activated PEG (e.g., the *p*-nitrophenyl carbonate derivative) to a mutin of porcine uricases. These examples provide guidance to one of ordinary skill in the art for producing substantially non-immunogenic conjugates of uricase that retain at least about 75% of the uricolytic activity of the unmodified enzyme and are well suited for chronic administration.

Example 1

Preparative ion-exchange chromatography of uricase

[0046] Preparative ion-exchange chromatography was performed on a Fast Protein Liquid Chromatography (FPLC) apparatus (Amersham Pharmacia, Piscataway, NJ). The Mono Q column (1 x 10 cm, Amersham Pharmacia) was eluted with a gradient of 50 mM sodium carbonate, pH 10.3, 0.1 M NaCl (Buffer A) to 50 mM sodium carbonate, pH 10.3, 0.6

M NaCl (Buffer B) at a flow rate of 0.5 ml/min, except that the sample was loaded at a lower flow-rate. This technique was used to fractionate 25 mL of a solution of PKS uricase (pH 10.3). PKS uricase was obtained from Bio-Technology General Limited (Rehovot, Israel). The latter is recombinant porcine uricase in which one residue of lysine (K) and one residue of serine (S) have replaced one residue of arginine and one residue of threonine, respectively, in the parental porcine sequence (Lee et al. (1988) Science 239:1288.1291; Wu et al. (1989) Proc. Natl Acad. Sci. U. S. A. 86:9412-9416). After the sample was loaded, the column was washed with 100 mL of Buffer A. The peak of uricase began to elute at the end of a 31-mL linear gradient of 0 to 26% Buffer 8. Most of the uricase was eluted isocratically by 7 mL of buffer containing 26% Buffer B. The remainder of the recovered uricase was eluted by a linear 89-mL gradient of 26% to 100% buffer B. Fractions of 4 mL or 6 mL were collected. Aliquots of Fractions #4-11 were assayed for uricase and total protein (Figure 1) and were analyzed by size-exclusion high performance liquid chromatography (HPLC) as described in Example 2 (Figures 2 and 3). The remaining portions of Fractions #5-10 were coupled to PEG, as described in Example 3. Based on the results of the analyses in Example 2, the PEG conjugates of Fractions #5 and 6 were combined as the "Low-Salt Pool" and the PEG conjugates of Fractions #7-10 were combined as the "High-Salt Pool," as indicated in Figure 1.

Example 2

Size-exclusion chromatography of uricase monitored by light scattering and ultraviolet absorbance

[0047] Size-exclusion HPLC was performed at room temperature on a Superdex 200 column (1 x 30 cm, Amersham Pharmacia Biotech) on unfractionated PKS uricase and on selected fractions from the preparative Mono Q chromatography of PKS uricase of Example 1. The eluate from the absorbance monitor (UV 2000) of the Thermo Separations HPLC (Sunnyvale, CA) was analyzed by light scattering at 90° to the incident light, using a MiniDawn detector from Wyatt Technologies (Santa Barbara, CA).

[0048] The results shown in Figures 2-4 illustrate the resolution among the tetramer, octamer and larger aggregates of the uricase subunit and the different proportions of the signals detected from these forms of uricase in the various samples. Unlike the absorbance signal, which is directly proportional to the concentration, the light scattering signal is proportional to the product of the concentration times the size of the light scattering unit. The resultant sensitivity of the light scattering detector to very small amounts of highly aggregated uricase revealed the presence of the largest aggregates, which are eluted at or near the void volume (approximately 7 mL).

Example 3

Synthesis of PEG-uricase conjugates

[0049] Unfractionated PKS uricase (from Bio-Technology General Limited) and the uricase in fractions from the Mono Q column of Example 1 were coupled to 10-kDa PEG using the *p*-nitrophenyl carbonate derivative of PEG (NPC-PEG) obtained from Shearwater Polymers (Huntsville, AL). The preparation of NPC-PEG from PEG using phenylchloroformates has been described in several reports (*e.g.* Veronese, FM, et al., (1985) Appl Biochem Biotechnol 11:141-152; Kito, M, et al., (1996) J Clin Biochem Nutr 21:101-111) and NPC-PEG has been used for the synthesis of PEG-protein conjugates by previous investigators including the present inventors (*e.g.* Veronese *et al.*, *supra*; Sherman, MR, et al., in JM Harris, et al., (Eds.) Polyethylene glycol Chemistry and Biological Applications. ACS Symposium Series 680 (pp. 155-176) Washington, DC: American Chemical Society). The number of strands of 10-kDa PEG coupled to each subunit of uricase was determined to be six by the method described by Kunitani, M, et al., (1991) J Chromatogr 588:125-137.

Example 4

In vivo serum persistence and immunogenicity of uricase and PEG-uricase

[0050] PEG conjugates of recombinant mammalian uricases, prepared according to the method of Example 3, were adjusted to 1 mg protein/mL in phosphate-buffered saline (PBS), pH 7.4, for injection. Samples were frozen and stored until analyzed or injected. Samples were warmed to 37°C for up to 1 hour prior to injection into groups of eight BALB/c female mice. The groups of mice had mean weights in the range of 18-22 g at the start of the studies.

[0051] The weights of all mice were monitored and evidence of adverse reactions to the injections or other evidence of ill health was recorded. Twenty-four hours after each of six weekly injections, the animals were anesthetized with ketamine and 100-200 μ L of blood was obtained retro-orbitally, except at sacrifice (exsanguination), when a larger volume was collected. Serum was prepared from blood that had clotted for between 4 and 32 hours at 2-8°C. Sera were stored at -20°C. Sera were analyzed for uricolytic activity as described in Example 5 and analyzed for antibodies against uricases as described in Example 6.

Example 5Uricolytic activity assays of PEG-uricase in sera from mice injected with PEG-uricase

5 **[0052]** An activity assay based on ultraviolet light absorbance (UV assay) was performed with 100 μ M uric acid as the substrate in 200 mM sodium borate, pH 9.2, in a microplate adaptation of the method of I. Fridovich (J Biol Chem. (1965) 240:2491-2494). The decrease in absorbance at 292 nm was monitored for 15 minutes at room temperature in a 96-well plate with a UV-transparent bottom (Costar, Corning, NY), using a SpectraMAX 250 microplate reader from Molecular Devices (Sunnyvale, CA). The data were analyzed by finding the maximum slope (in milli-absorbance units per minute) of absorbance measurements made during the interval while between 10 and 40% of the substrate was oxidized. Results obtained with this assay are illustrated in Figures 1 and 5.

10 **[0053]** The mean half-life in sera of mice injected for the first time with PKS uricase coupled to six strands of 10-kDa PEG per subunit (6 x 10-kDa PEG PKS) was 29 ± 4 hours, based on data from sera obtained 24 and 72 hours after the injection.

15 **[0054]** In separate experiments, it was established that the detectable uricolytic activity in the sera of mice injected with PEG-uricase declines during storage at -20°C and that maximal recovery of this activity is obtained by a 4-hour incubation at 37° prior to assay. Figure 5 shows that the recovery of uricolytic activity after repeated weekly injections of 6 x 10-kDa PEG PKS uricase was greatest when the enzyme was purified by Mono Q column chromatography, as in Example 1, prior to PEGylation according to the method of Example 3. Recovery was highest after the injection of
 20 conjugates prepared from the high-salt eluate pool of Example 1 (see Figure 1), which has the smallest content of the very large aggregates (see the light scattering profiles of Fractions 7-10 in Figure 3). Intermediate recovery was obtained with conjugates prepared from the low-salt eluate pool from the Mono Q column of Example 1, and the poorest recovery was obtained with conjugates made from unfractionated PKS uricase, which has the highest content of very large
 25 aggregates (see Figure 2). The same order of relative activities recovered in sera after repeated injections (high salt pool > low salt pool > unfractionated uricase) was observed regardless of whether the UV assay described above or a colorimetric assay adapted from P. Fossati et al. (J. Clin Chem (1980) 26:227-231), was used and regardless of whether the sera were incubated at 37°C before they were assayed.

Example 6

30 **[0055]** Enzyme-linked immunosorbent assay (ELISA) of sera from mice injected with PEG-uricase Non-competitive ELISA analyses were performed with porcine uricase bound to 96-well Immulon 2 plates (Dynerx Technologies, from VWR Scientific, San Francisco, CA). The primary antisera were from mice injected with uricase or 6 x 10-kDa PEG
 35 conjugates prepared according to the method of Example 3. The secondary antibody was goat anti-mouse IgG coupled to horseradish peroxidase (Calbiochem-Novabiochem #401 253, La Jolla, CA) and the substrate was o-phenylenediamine dihydrochloride (Sigma P-9187, St. Louis, MO), as described by B. Porstmann et al. (J Clin. Chem. Clin. Biochem. (1981) 19:435-440).

40 **[0056]** Figure 6 illustrates the results of the non-competitive ELISA analyses. The results demonstrate that the 6 x 10-kDa PEG PKS uricase synthesized according to the method of Example 3 from the high-salt eluate from the Mono Q column of Example 1 (shown in Figure 1) did not produce detectable immune responses in any of the eight mice that received weekly injections for six weeks. A few mice injected with conjugates prepared from unfractionated PKS uricase according to the method of Example 3 showed low but detectable immune responses. The highest incidence of immune responses was in mice injected with conjugates prepared according to the method of Example 3 from the low-salt eluate pool from the Mono Q column of Example 1.

45 **[0057]** Without the benefit of the light scattering detector for the size-exclusion HPLC analyses, as described in Example 2, it would not have been apparent that the presence of the largest aggregates, not of the octameric form of uricase, is associated with progressively decreased recovery of PEG-uricase conjugates after repeated injections, as observed in Example 5 (Figure 5) and with an increase in immunogenicity in BALB/c mice, as observed in Example 6 (Figure 6). These results have important implications for the specifications of the uricase used as a starting material for the production
 50 of PEG-uricase for clinical use.

[0058] The specification describes disclosures E1 to E33.

E1. Purified urate oxidase (uricase) substantially free of aggregates larger than octamers.

E2. The uricase of E1, wherein the uricase is mammalian uricase

55 E3. The uricase of E2, wherein the uricase is porcine liver, bovine liver or ovine liver uricase.

E4. The uricase of E1, wherein the uricase is recombinant.

E5. The uricase of E4, wherein the uricase has substantially the sequence of porcine, bovine, ovine or baboon liver uricase.

EP 2 196 538 B1

- E6. The uricase of E4, wherein the uricase is chimeric.
- E7. The uricase of E6, wherein the chimeric uricase contains portions of porcine liver and baboon liver uricase.
- E8. The uricase of E7, wherein the chimeric uricase is PKS uricase.
- 5 E9. The uricase of E4, wherein the uricase has substantially the sequence of baboon liver uricase in which tyrosine 97 has been replaced by histidine.
- E10. The uricase of E4, wherein the uricase comprises an amino terminal and a carboxy terminus, and wherein the uricase is truncated at one terminus or both termini.
- E11. The uricase of E1, wherein the uricase is a fungal or microbial uricase.
- 10 E12. The uricase of E11, wherein the fungal or microbial uricase is isolated from *Aspergillus flavus*, *Arthrobacter globiformis*, *Bacillus sp.* or *Candida utilis*. or is a recombinant enzyme having substantially the sequence of one of said uricases.
- E13. The uricase of E1, wherein the uricase is an invertebrate uricase.
- E14. The uricase of E13, wherein the invertebrate uricase is isolated from *Drosophila melanogaster* or *Drosophila pseudoobscura*, or is a recombinant enzyme having substantially the sequence of one of said uricases.
- 15 E15. The uricase of E1, wherein the uricase is a plant uricase.
- E16. The uricase of E15, wherein the plant uricase is isolated from root nodules of *Glycine max* or is a recombinant enzyme having substantially the sequence of said uricase.
- E17. The uricase of E1 conjugated to poly(ethylene glycol) or poly(ethylene oxide), wherein the uricase in said conjugate is substantially free of aggregates larger than octamers.
- 20 E18. The uricase conjugate of E17, wherein said poly(ethylene glycol) is monomethoxy poly(ethylene glycol).
- E19. The uricase of E17, wherein said uricase is conjugated to said poly(ethylene glycol) or poly(ethylene oxide) via a linkage selected from the group consisting of urethane (carbamide), secondary amine and amide
- E20. The uricase conjugate of E17, wherein said poly(ethylene glycol) or poly(ethylene oxide) has a molecular weight between about 5 kDa and 30 kDa.
- 25 E21. The uricase conjugate of E20, wherein said poly(ethylene glycol) or poly(ethylene oxide) has a molecular weight between about 10 kDa and 20 kDa.
- E22. The uricase conjugate of E17, wherein the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) strands is between about 2 and 12 per uricase subunit.
- E23. The uricase conjugate of E22 wherein the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) strands is between about 6 and 10 per uricase subunit.
- 30 E24. The uricase conjugate of E23, wherein the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) is between about 7 and 9 per uricase subunit.
- E25. The uricase conjugate of E17, wherein the poly(ethylene glycol) or poly(ethylene oxide) is linear.
- E26. The uricase conjugate of E17, wherein the poly(ethylene glycol) or poly(ethylene oxide) is branched.
- 35 E27. A pharmaceutical composition for lowering uric acid levels in a body fluid or tissue, comprising the conjugate of E17 and a pharmaceutically acceptable carrier.
- E28. The pharmaceutical composition of E27, wherein said composition is stabilized by lyophilization and dissolves upon reconstitution to provide solutions suitable for parenteral administration.
- E29. A method for purifying uricase having reduced immunogenicity, comprising the step of separating uricase aggregates larger than octamers in uricase fractions, and excluding such aggregates from the purified uricase.
- 40 E30. The method of E29, wherein said separating step is selected from the group consisting of ion-exchange chromatography, size-exclusion chromatography and ultrafiltration.
- E31. The method of E30, wherein said separating step comprises the step of detecting aggregates larger than octamers in uricase fractions and excluding said fractions containing said aggregates.
- 45 E32. The method of E31, wherein said detecting step comprises measurement of light scattering.
- E33. Isolated uricase prepared by the method of E29.

SEQUENCE LISTING

50 **[0059]**

<110> Mountain View Pharmaceuticals, Inc. Duke University

<120> Conjugates Prepared With Aggregate-Free Proteins

55

<130> P32274EP-D1-PCT

<140> Not yet assigned

EP 2 196 538 B1

<141> 2001-02-07

<150> US 09/501,730

<151> 2000-02-10

5

<160> 3

<170> PatentIn version 3.3

10

<210> 1

<211> 304

<212> PRT

<213> Sus scrofa

15

<400> 1

Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
1 5 10 15

20

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
20 25 30

25

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
35 40 45

30

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
50 55 60

35

Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65 70 75 80

Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
85 90 95

40

His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

45

Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
115 120 125

50

55

EP 2 196 538 B1

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
 130 135 140
 5
 Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
 145 150 155 160
 10
 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
 165 170 175
 15
 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
 180 185 190
 Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
 195 200 205
 20
 Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
 210 215 220
 25
 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
 225 230 235 240
 30
 Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
 245 250 255
 35
 Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys
 260 265 270
 40
 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
 275 280 285
 Tyr Gly Arg Ile Thr Gly Thr Val Lys Arg Lys Leu Thr Ser Arg Leu
 290 295 300
 <210> 2
 <211> 304
 <212> PRT
 45 <213> Papio hamadryas
 <400> 2
 50 Met Ala Asp Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Leu Glu Phe
 1 5 10 15
 Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln
 55

EP 2 196 538 B1

5	Arg	Asp	Gly	Lys	Tyr	His	Ser	Ile	Lys	Glu	Val	Ala	Thr	Ser	Val	Gln	
			35					40					45				
10	Leu	Thr	Leu	Ser	Ser	Lys	Lys	Asp	Tyr	Leu	His	Gly	Asp	Asn	Ser	Asp	
		50					55					60					
15	Ile	Ile	Pro	Thr	Asp	Thr	Ile	Lys	Asn	Thr	Val	His	Val	Leu	Ala	Lys	
	65					70					75					80	
20	Phe	Lys	Gly	Ile	Lys	Ser	Ile	Glu	Ala	Phe	Gly	Val	Asn	Ile	Cys	Glu	
					85					90					95		
25	Tyr	Phe	Leu	Ser	Ser	Phe	Asn	His	Val	Ile	Arg	Ala	Gln	Val	Tyr	Val	
				100					105					110			
30	Glu	Glu	Ile	Pro	Trp	Lys	Arg	Leu	Glu	Lys	Asn	Gly	Val	Lys	His	Val	
			115					120					125				
35	His	Ala	Phe	Ile	His	Thr	Pro	Thr	Gly	Thr	His	Phe	Leu	Glu	Val	Glu	
		130					135					140					
40	Gln	Leu	Arg	Ser	Gly	Pro	Pro	Val	Ile	His	Ser	Gly	Ile	Lys	Asp	Leu	
	145					150					155					160	
45	Lys	Val	Leu	Lys	Thr	Thr	Gln	Ser	Gly	Phe	Glu	Gly	Phe	Ile	Lys	Asp	
					165					170					175		
50	Gln	Phe	Thr	Thr	Lys	Pro	Glu	Val	Lys	Asp	Arg	Cys	Phe	Ala	Thr	Gln	
				180					185					190			
55	Val	Tyr	Cys	Lys	Trp	Arg	Tyr	His	Gln	Cys	Arg	Asp	Val	Asp	Phe	Glu	
			195				200						205				
60	Ala	Thr	Trp	Gly	Thr	Ile	Arg	Asp	Leu	Val	Leu	Glu	Lys	Phe	Ala	Gly	
		210					215					220					
65	Pro	Tyr	Asp	Lys	Gly	Glu	Tyr	Ser	Pro	Ser	Val	Gln	Lys	Thr	Leu	Tyr	
	225					230					235					240	
70	Asp	Ile	Gln	Val	Leu	Ser	Leu	Ser	Arg	Val	Pro	Glu	Ile	Glu	Asp	Met	
				245						250					255		

EP 2 196 538 B1

Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
260 265 270

5 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

10 Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
290 295 300

<210> 3
<211> 304
<212> PRT
15 <213> Artificial Sequence

<220>
<223> Chimera of Sus scrofa and Papio hamadryas

20 <400> 3

Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
1 5 10 15

25 Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
20 25 30

30 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
35 40 45

35 Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
50 55 60

40 Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65 70 75 80

45 Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
85 90 95

50 His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

55 Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
115 120 125

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu

EP 2 196 538 B1

130 135 140

5 Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145 150 155 160

10 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

15 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
180 185 190

20 Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
195 200 205

25 Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
210 215 220

30 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

35 Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
245 250 255

40 Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys
260 265 270

45 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

50 Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
290 295 300

Claims

1. A protein conjugate comprising a purified protein conjugated to poly(ethylene glycol) or poly(ethylene oxide), wherein
45 said protein is preparable by removing aggregates larger than octamers detectable by light scattering, wherein said
protein contains no more than about 2% of aggregates larger than octamers, wherein the conjugate has reduced
immunogenicity compared to a conjugate comprising the same protein from which aggregates larger than octamers
of said protein have not been separated prior to said protein being covalently linked to said poly(ethylene glycol) or
poly(ethylene oxide), and wherein said protein is a growth factor or an interferon.
50
2. The protein conjugate of claim 1, wherein said poly(ethylene glycol) or poly(ethylene oxide) has a molecular weight
of between about 8 kDa and 60 kDa.
3. The protein conjugate of claim 1, wherein said protein is selected from the group consisting of a naturally occurring
55 protein and a recombinant protein.
4. The protein conjugate of claim 1, wherein said protein is a growth factor.

5. The protein conjugate of claim 1, wherein said protein is an interferon.
6. The protein conjugate of claim 5, wherein said interferon is interferon-alpha.
- 5 7. The protein conjugate of claim 1, wherein said poly(ethylene glycol) is monomethoxypoly(ethylene glycol).
8. The protein conjugate of claim 1, wherein said protein is conjugated to said poly(ethylene glycol) or poly(ethylene oxide) via a linkage selected from the group consisting of a urethane (carbamate) linkage, a secondary amine linkage and an amide linkage.
- 10 9. The protein conjugate of claim 1, wherein the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) that are covalently linked to said protein is between 2 and 12.
- 15 10. The protein conjugate of claim 1, wherein said poly(ethylene glycol) or poly(ethylene oxide) is linear.
11. The protein conjugate of claim 1, wherein said poly(ethylene glycol) or poly(ethylene oxide) is branched.
12. A method for preparing a protein conjugate as defined in claim 1, comprising:
- 20 (a) preparing an isolated protein that is substantially free of aggregates larger than octamers of said protein by:
- (i) preparing a solution of said protein in a suitable solvent;
- (ii) separating said protein solution by a separation method, whereby a plurality of fractions of said protein is obtained;
- 25 (iii) detecting aggregates larger than octamers of said protein during or following said separation by measuring the light scattering of each of said fractions; and
- (iv) excluding the fractions of said protein that contain aggregates larger than octamers of said protein from those fractions that are substantially free of aggregates larger than octamers of said protein; and
- 30 (b) covalently linking the isolated protein to one or more poly(ethylene glycol) or poly(ethylene oxide) molecules, wherein said protein is a growth factor or an interferon.
13. The method of claim 12, wherein said separation process is selected from the group consisting of ion-exchange chromatography, size-exclusion chromatography and ultrafiltration.
- 35 14. The method of claim 12, wherein said protein is selected from the group consisting of a naturally occurring protein and a recombinant protein.
15. The method of claim 12, wherein said protein is a growth factor.
- 40 16. The method of claim 12, wherein said protein is an interferon.
17. The method of claim 16, wherein said interferon is interferon-alpha.
- 45 18. The method of claim 12, wherein said poly(ethylene glycol) or poly(ethylene oxide) has a molecular weight of between about 8 kDa and 60 kDa.
19. The method of claim 18, wherein said poly(ethylene glycol) is monomethoxypoly(ethylene glycol).
- 50 20. The method of claim 18, wherein said isolated protein is conjugated to said poly(ethylene glycol) or poly(ethylene oxide) via a linkage selected from the group consisting of a urethane (carbamate) linkage, a secondary amine linkage and an amide linkage.
21. The method of claim 18, wherein the average number of strands of said poly(ethylene glycol) or poly(ethylene oxide) that are covalently linked to said protein is between 2 and 12.
- 55 22. The method of claim 18, wherein said poly(ethylene glycol) or poly(ethylene oxide) is linear.

23. The method of claim 18, wherein said poly(ethylene glycol) or poly(ethylene oxide) is branched.
24. A pharmaceutical composition comprising the protein conjugate of claim 1 and one or more pharmaceutically acceptable excipients.
25. The pharmaceutical composition of claim 24, wherein said composition is a sterile powder which dissolves upon reconstitution to provide a solution suitable for parenteral administration.

5

10 **Patentansprüche**

1. Proteinkonjugat, das ein gereinigtes Protein, konjugiert an Poly(ethylenglykol) oder Poly(ethylenoxid), beinhaltet, wobei das genannte Protein durch Entfernen von Aggregaten hergestellt werden kann, die größer als Oktamere sind, detektierbar anhand von Lichtstreuung, wobei das Protein nicht mehr als etwa 2 % Aggregate enthält, die größer als Oktamere sind, wobei das Konjugat eine reduzierte Immunogenität im Vergleich zu einem Konjugat hat, das das gleiche Protein beinhaltet, von dem Aggregate, die größer als Oktamere des Proteins sind, nicht abgetrennt wurden, bevor das Protein kovalent an das Poly(ethylenglykol) oder Poly(ethylenoxid) gebunden wurde, und wobei das Protein ein Wachstumsfaktor oder ein Interferon ist.
2. Proteinkonjugat nach Anspruch 1, wobei das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) ein Molekulargewicht zwischen etwa 8 kDa und 60 kDa hat.
3. Proteinkonjugat nach Anspruch 1, wobei das genannte Protein aus der Gruppe bestehend aus einem natürlich vorkommenden Protein und einem rekombinanten Protein ausgewählt ist.
4. Proteinkonjugat nach Anspruch 1, wobei das genannte Protein ein Wachstumsfaktor ist.
5. Proteinkonjugat nach Anspruch 1, wobei das genannte Protein ein Interferon ist.
6. Proteinkonjugat nach Anspruch 5, wobei das genannte Interferon Interferon-alpha ist.
7. Proteinkonjugat nach Anspruch 1, wobei das genannte Poly(ethylenglykol) Monomethoxypoly(ethylenglykol) ist.
8. Proteinkonjugat nach Anspruch 1, wobei das genannte Protein über eine Bindung an das Poly(ethylenglykol) oder Poly(ethylenoxid) konjugiert ist, die ausgewählt ist aus der Gruppe bestehend aus einer Urethan(carbamat)bindung, einer sekundären Aminbindung und einer Amidbindung.
9. Proteinkonjugat nach Anspruch 1, wobei die mittlere Anzahl von Strängen des Poly(ethylenglykols) oder Poly(ethylenoxids), die kovalent an das Protein gebunden sind, zwischen 2 und 12 liegt.
10. Proteinkonjugat nach Anspruch 1, wobei das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) linear ist.
11. Proteinkonjugat nach Anspruch 1, wobei das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) verzweigt ist.
12. Verfahren zur Herstellung eines Proteinkonjugats nach Anspruch 1, das Folgendes beinhaltet:
- (a) Herstellen eines isolierten Proteins, das im Wesentlichen frei von Aggregaten ist, die größer als Oktamere des genannten Proteins sind, durch:
- (i) Herstellen einer Lösung des genannten Proteins in einem geeigneten Lösungsmittel;
- (ii) Abtrennen der Proteinlösung mit einem Abtrennungsverfahren, so dass mehrere Fraktionen des genannten Proteins erhalten werden;
- (iii) Detektieren von Aggregaten, die größer als Oktamere des genannten Proteins sind, während oder nach der Abtrennung durch Messen der Lichtstreuung von jeder der Fraktionen; und
- (iv) Ausschließen der Fraktionen des genannten Proteins, die Aggregate enthalten, die größer als Oktamere des genannten Proteins sind, von Fraktionen, die im Wesentlichen frei von Aggregaten sind, die größer als Oktamere des genannten Proteins sind; und

15

20

25

30

35

40

45

50

55

EP 2 196 538 B1

(b) kovalentes Binden des isolierten Proteins an ein oder mehrere Poly(ethylenglykol)- oder Poly(ethylenoxid)moleküle, wobei das genannte Protein ein Wachstumsfaktor oder ein Interferon ist.

- 5 13. Verfahren nach Anspruch 12, wobei der genannte Abtrennungsprozess aus der Gruppe bestehend aus Ionenaustauschchromatographie, Größenausschlusschromatographie und Ultrafiltration ausgewählt wird.
14. Verfahren nach Anspruch 12, wobei das genannte Protein aus der Gruppe bestehend aus einem natürlich vorkommenden Protein und einem rekombinanten Protein ausgewählt wird.
- 10 15. Verfahren nach Anspruch 12, wobei das genannte Protein ein Wachstumsfaktor ist.
16. Verfahren nach Anspruch 12, wobei das genannte Protein ein Interferon ist.
17. Verfahren nach Anspruch 16, wobei das genannte Interferon Interferon-alpha ist.
- 15 18. Verfahren nach Anspruch 12, wobei das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) ein Molekulargewicht zwischen etwa 8 kDa und 60 kDa hat.
- 20 19. Verfahren nach Anspruch 18, wobei das genannte Poly(ethylenglykol) Monomethoxypoly(ethylenglykol) ist.
20. Verfahren nach Anspruch 18, wobei das genannte isolierte Protein über eine Bindung an das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) konjugiert wird, die ausgewählt wird aus der Gruppe bestehend aus einer Urethan(carbamat)bindung, einer sekundären Aminbindung und einer Amidbindung.
- 25 21. Verfahren nach Anspruch 18, wobei die mittlere Anzahl von Strängen des genannten Poly(ethylenglykols) oder Poly(ethylenoxids), die an das Protein kovalent gebunden werden, zwischen 2 und 12 liegt.
22. Verfahren nach Anspruch 18, wobei das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) linear ist.
- 30 23. Verfahren nach Anspruch 18, wobei das genannte Poly(ethylenglykol) oder Poly(ethylenoxid) verzweigt ist.
24. Pharmazeutische Zusammensetzung, die das Proteinkonjugat nach Anspruch 1 und einen oder mehrere pharmazeutisch verträgliche Exzipienten beinhaltet.
- 35 25. Pharmazeutische Zusammensetzung nach Anspruch 24, wobei die genannte Zusammensetzung ein steriles Pulver ist, das sich bei Rekonstitution löst, wodurch eine Lösung entsteht, die für eine parenterale Verabreichung geeignet ist.

40 **Revendications**

- 45 1. Conjugué de protéine comprenant une protéine purifiée conjuguée à du poly(éthylène glycol) ou à du poly(oxyde d'éthylène), dans lequel ladite protéine peut être préparée par élimination des agrégats plus gros que des octamères détectables par diffusion de la lumière, dans lequel ladite protéine ne contient pas plus d'environ 2 % d'agrégats plus gros que des octamères, le conjugué présentant une immunogénicité réduite par comparaison avec un conjugué comprenant la même protéine à partir duquel les agrégats plus gros que des octamères de ladite protéine n'ont pas été séparés avant la liaison de façon covalente de ladite protéine audit poly(éthylène glycol) ou poly(oxyde d'éthylène), et ladite protéine étant un facteur de croissance ou un interféron.
- 50 2. Conjugué de protéine selon la revendication 1, dans lequel ledit poly(éthylène glycol) ou poly(oxyde d'éthylène) a une masse moléculaire comprise entre environ 8 kDa et 60 kDa.
3. Conjugué de protéine selon la revendication 1, dans lequel ladite protéine est sélectionnée dans le groupe constitué d'une protéine présente à l'état naturel et d'une protéine recombinée.
- 55 4. Conjugué de protéine selon la revendication 1, dans lequel ladite protéine est un facteur de croissance.
5. Conjugué de protéine selon la revendication 1, dans lequel ladite protéine est un interféron.

6. Conjugué de protéine selon la revendication 5, dans lequel ledit interféron est un interféron alpha.
7. Conjugué de protéine selon la revendication 1, dans lequel ledit poly(éthylène glycol) est du polyéthylène glycol monométhoxylé.
- 5 8. Conjugué de protéine selon la revendication 1, dans lequel ladite protéine est conjuguée audit poly(éthylène glycol) ou poly(oxyde d'éthylène) par l'intermédiaire d'une liaison sélectionnée dans le groupe constitué d'une liaison uréthane (carbamate), d'une liaison amine secondaire et d'une liaison amide.
- 10 9. Conjugué de protéine selon la revendication 1, dans lequel le nombre moyen de brins dudit poly(éthylène glycol) ou poly(oxyde d'éthylène) qui sont liés de façon covalente à ladite protéine est compris entre 2 et 12.
- 15 10. Conjugué de protéine selon la revendication 1, dans lequel ledit poly(éthylène glycol) ou poly(oxyde d'éthylène) est linéaire.
- 15 11. Conjugué de protéine selon la revendication 1, dans lequel ledit poly(éthylène glycol) ou poly(oxyde d'éthylène) est ramifié.
- 20 12. Procédé pour préparer un conjugué de protéine tel que défini dans la revendication 1, comprenant les étapes consistant à :
- (a) préparer une protéine isolée qui ne contient pratiquement pas d'agrégats plus gros que des octamères de ladite protéine en :
- 25 (i) préparant une solution de ladite protéine dans un solvant convenant à cette fin ;
(ii) séparant ladite solution de protéine par un procédé de séparation, une pluralité de fractions de ladite protéine étant ainsi obtenue ;
(iii) détectant les agrégats plus gros que des octamères de ladite protéine pendant ou après ladite séparation en mesurant la diffusion de la lumière pour chacune desdites fractions ; et
- 30 (iv) excluant les fractions de ladite protéine qui contiennent des agrégats plus gros que des octamères de ladite protéine des fractions qui ne contiennent pratiquement pas d'agrégats plus gros que des octamères de ladite protéine ; et
- (b) lier de façon covalente la protéine isolée à une ou plusieurs molécules de poly(éthylène glycol) ou de poly(oxyde d'éthylène), ladite protéine étant un facteur de croissance ou un interféron.
- 35 13. Procédé selon la revendication 12, dans lequel ledit procédé de séparation est sélectionné dans le groupe constitué d'une chromatographie par échange d'ions, d'une chromatographie par exclusion de tailles et d'une ultrafiltration.
- 40 14. Procédé selon la revendication 12, dans lequel ladite protéine est sélectionnée dans le groupe constitué d'une protéine présente à l'état naturel et d'une protéine recombinée.
15. Procédé selon la revendication 12, dans lequel ladite protéine est un facteur de croissance.
- 45 16. Procédé selon la revendication 12, dans lequel ladite protéine est un interféron.
17. Procédé selon la revendication 16, dans lequel ledit interféron est un interféron alpha.
- 50 18. Procédé selon la revendication 12, dans lequel ledit poly(éthylène glycol) ou poly(oxyde d'éthylène) a une masse moléculaire comprise entre environ 8 kDa et 60 kDa.
19. Procédé selon la revendication 18, dans lequel ledit poly(éthylène glycol) est du polyéthylène glycol monométhoxylé.
- 55 20. Procédé selon la revendication 18, dans lequel ladite protéine isolée est conjuguée audit poly(éthylène glycol) ou poly(oxyde d'éthylène) par l'intermédiaire d'une liaison sélectionnée dans le groupe constitué d'une liaison uréthane (carbamate), d'une liaison amine secondaire et d'une liaison amide.
21. Procédé selon la revendication 18, dans lequel le nombre moyen de brins dudit poly(éthylène glycol) ou poly(oxyde

EP 2 196 538 B1

d'éthylène) qui sont liés de façon covalente à ladite protéine est compris entre 2 et 12.

22. Procédé selon la revendication 18, dans lequel ledit poly(éthylène glycol) ou poly(oxyde d'éthylène) est linéaire.

5 **23.** Procédé selon la revendication 18, dans lequel ledit poly(éthylène glycol) ou poly(oxyde d'éthylène) est ramifié.

24. Composition pharmaceutique comprenant le conjugué de protéine selon la revendication 1 et un ou plusieurs excipients acceptables en pharmacie.

10 **25.** Composition pharmaceutique selon la revendication 24, ladite composition étant une poudre stérile qui se dissout lors d'une reconstitution pour former une solution adaptée à une administration par voie parentérale.

15

20

25

30

35

40

45

50

55

Figure 1

UV Assay of Uricolytic Activity in Fractions from Mono Q Chromatography of PKS Uricase
 (Protein Based on Size-Exclusion HPLC)




Figure 2

Size-Exclusion HPLC on Superdex 200 of Unfractionated PKS Uricase (Load) and Mono Q Column Fractions in the Low-Salt Pool




Figure 3




Figure 4

Octamer Content of Mono Q Column Fractions of PKS Urlicase





Figure 5


**UV Uricase Assays of Sera from Mice Injected with 6 x 10-kDa PEG
Conjugates of PKS Uricase or of Pools from Mono Q Column Fractions
Mice Were Bled 24 Hours after Each Weekly Injection.**



Data for the Low-Salt and High-Salt Pools were shifted on the x-axis by 0.1 and 0.2 units, respectively.

Figure 6

ELISA Analyses with Pig Uricase on the Plate and 1:30 Sera from Mice Injected with 6 x 10-kDa PEG Conjugates of Unfractionated PKS Uricase or Low-Salt or High-Salt Pools



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 370084 A [0005] [0025]
- US 9917514 W [0005]
- WO 0007629 A [0009]
- WO 8700056 A [0010]
- WO 9216221 A [0011]
- WO 9423740 A [0012]
- US 5643575 A [0027]
- WO 0008196 A [0029]
- US 5612460 A [0032]
- US 5286637 A [0032]
- DD 279486 A1 [0032]
- US 5458135 A [0041]
- US 5653974 A [0043]
- US 09501730 B [0059]

Non-patent literature cited in the description

- **WU, X et al.** *J mol Evol*, 1992, vol. 34, 78-84 [0004]
- **HANDE, KR et al.** *Am J Med*, 1984, vol. 76, 47-56 [0004]
- **FAM, AG.** *Baillière's Clin Rheumatol*, 1990, vol. 4, 177-192 [0004]
- **PUI, C-H et al.** *Leukemia*, 1997, vol. 11, 1813-1816 [0004]
- **DONADIO, D et al.** *Nouv Presse Méd*, 1981, vol. 10, 711-712 [0004]
- **LEAUSTIC, M et al.** *Rev Rhum Mal Osteoartic*, 1983, vol. 50, 553-554 [0004]
- **HENNEY et al.** *N. Engl. J. Med.*, 1968, vol. 278, 2244-2246 [0007]
- **MOORE et al.** *J. Clin. Endocrinol Metab.*, 1980, vol. 51, 691-697 [0007]
- **BRAUN et al.** *Pharm. Res.*, 1997, vol. 14, 1472-1478 [0007]
- **BRAUN et al.** *Pharm. Res.*, 1997, vol. 14, 1394-1400 [0007]
- **SHARMA et al.** *Biotechnology Advances*, 2007, vol. 25 (3), 325-331 [0013]
- **ROSENBERG et al.** *AAPS Journal*, 2006, vol. 8 (3), E501-E507 [0014]
- PCR Technology. Principles and Applications for DNA Amplification. Stockton Press, 1989 [0030]
- **SAMBROOK, J et al.** *Molecular Cloning. A laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0030]
- **FRIDOVICH, I.** *J Biol Chem*, 1965, vol. 240, 2491-2494 [0030]
- **VERONESE, FM et al.** *Appl Biochem Biotechnol*, 1985, vol. 11, 141-152 [0032] [0049]
- **MOORE, WV et al.** *J Clin Endocrinol Metab*, 1980, vol. 51, 691-697 [0038]
- **PATTON, JS.** *Adv Drug Delivery Rev*, 1996, vol. 19, 3-36 [0041]
- **VENKATASESHAN, VS.** *Nephron*, 1990, vol. 56, 317-321 [0044]
- **LEE et al.** *Science*, 1988, vol. 239, 1288-1291 [0046]
- **WU et al.** *Proc. Natl Acad. Sci. U. S. A.*, 1989, vol. 86, 9412-9416 [0046]
- **KITO, M et al.** *J Clin Biochem Nutr*, 1996, vol. 21, 101-111 [0049]
- **SHERMAN, MR et al.** *Polyethylene glycol Chemistry and Biological Applications*. ACS Symposium Series 680. American Chemical Society, 155-176 [0049]
- **KUNITANI, M et al.** *J Chromatogr*, 1991, vol. 588, 125-137 [0049]
- **I. FRIDOVICH.** *J Biol Chem*, 1965, vol. 240, 2491-2494 [0052]
- **P. FOSSATI et al.** *J. Clin Chem*, 1980, vol. 26, 227-231 [0054]
- **B. PORSTMANN et al.** *J Clin. Chem. Clin. Biochem.*, 1981, vol. 19, 435-440 [0055]